David M. Mott, Director at Mersana Therapeutics, Inc. (MRSN), bought 1,077,198 shares at $5.59 ($6.0M) on 2020-04-07, disclosed to the SEC on 2020-04-09.
Open-market purchase of $6.0M MRSN by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.59 | 538,599 | $3.0M | 50.0% |
| 2 | $5.59 | 538,599 | $3.0M | 50.0% |
| Total | $5.59 avg | 1,077,198 | $6.0M | 100% |
| Filing → |
| ARDX | BUY | 2025-06-11 | $738K | — | Filing → |
| ARDX | BUY | 2025-05-19 | $329K | — | Filing → |
| ARDX | BUY | 2025-05-05 | $3.2M | — | Filing → |